• Quick Order
  • Careers
  • Support


Checkpoint inhibitor therapeutic antibody blocking PD-1 protein on T cell and preventing it to bind to PD-1L on cancer cell

Fight cancer with the power of the immune system


Cancer immunotherapy has emerged as an exciting new approach for cancer treatment, and immuno-oncology is one of the fastest growing fields in oncology. As compared to traditional cancer therapies that act directly on cancerous tumors, immuno-oncology therapy offers a unique approach that uses the body’s immune system to selectively target and eradicate tumor cells. These therapies also provide long-lasting memory to the immune system, enabling it to continue fighting against cancer cells even after remission.

The development of immunomodulatory drugs and biologics dictates a clear need for human cell-based models to evaluate immune activation. To answer this need, ATCC provides a large collection of fully characterized and authenticated cell lines, human primary cells, and advanced cell models.

We are offering 10% off Checkpoint and CAR-T Target Reporter Models* Use promo code ATCC-000028 at checkout to take advantage of this special discount. This limited-time offer is effective from April 1 - May 15, 2024, so place your order before time runs out!

*Offer is effective from April 1st – May 15th, 2024. The 10% discount applies only to ATCC Checkpoint and CAR-T Target Reporter Models; all other items are excluded from this promotion. For non-profit customers, the promotional discount is applied to the customer-specific pricing. The promo code must be applied at the time of checkout. The promo code must be applied in the “Promotional code” field in the shopping cart. U.S. customers only. Void where prohibited. Restrictions may apply. Limit 20 vials.

Explore our immuno-oncology products and resources

Refine by